Beyond Hematological Malignancies: the Case for PI3K Inhibition in Brain Cancer

Time: 11:15 am
day: Day Two


• Relevance of the PI3K pathway to primary and secondary brain cancers
• Opportunities and challenges in the application of PI3K inhibitors to brain cancer Paxalisib – a novel PI3K / mTOR inhibitor in development for glioblastoma